Esperion Stock Downgraded by BofA Due to Rising Competition from Merck
BofA Securities has downgraded Esperion's stock due to increased competition from pharmaceutical giant Merck. The price target for Esperion shares has been adjusted to $2.50, down from the previous $2.90.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
